Dae Hwa Pharm Co Ltd
Dae Hwa Pharm Co Ltd is a South Korean pharmaceutical company that develops, produces, and distributes generic and branded drugs, primarily in the domestic market.
Business. Dae Hwa Pharm Co Ltd (067080.KQ) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in South Korea and operates within the broader Healthcare sector. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Dae Hwa Pharm Co Ltd (067080.KQ) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in South Korea and operates within the broader Healthcare sector. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Dae Hwa Pharm Co Ltd has a market capitalization of KRW 241.31 billion and a price-to-earnings ratio of 145.94, indicating a high valuation relative to its earnings. The company's price-to-book ratio of 3.26 suggests that the market is valuing its equity at more than three times its book value. The liquidity position is weak, with a current ratio of 0.51 and negative net cash after subtracting total debt, signaling potential short-term liquidity constraints.
The company's profitability metrics are below typical industry benchmarks. Return on equity (ROE) is 2.23%, and return on assets (ROA) is 0.78%, both of which are significantly lower than the median for the pharmaceutical industry. The operating margin is 5.27% (calculated from operating income of KRW 7.54 billion on revenue of KRW 143.06 billion), which is also below the industry median for profitability.
Dae Hwa Pharm Co Ltd's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. The company's business is entirely within the pharmaceuticals segment, with no diversification into other healthcare subsectors. This lack of geographic and product diversification increases exposure to domestic regulatory and economic risks.
The company's growth trajectory is modest. Revenue in the latest period was KRW 143.06 billion, with no disclosed year-over-year growth rate. The outlook for the current fiscal year is neutral, with no significant revenue growth expected. The company's capital expenditures were negative KRW 4.73 billion, indicating asset disposals or a reduction in investment.
The risk profile of Dae Hwa Pharm Co Ltd includes medium liquidity risk and low dilution risk. The company has a debt-to-equity ratio of 1.31, indicating a leveraged capital structure. The risk assessment highlights the negative net cash position as a key flag, which could constrain operational flexibility.
Recent filings and transcripts do not indicate any material events or strategic shifts. The company has not disclosed any new product launches, regulatory approvals, or significant partnerships in the latest available documents. The absence of recent strategic activity suggests a stable but stagnant business model.
- Dae Hwa Pharm Co Ltd is highly valued relative to earnings but underperforms in profitability metrics.
- The company's liquidity position is weak, with a current ratio of 0.51 and negative net cash.
- Revenue and product concentration in South Korea and the pharmaceuticals segment increases exposure to domestic risks.
- Growth is limited, with no significant revenue expansion or capital investment in the latest period.
- The risk profile is moderate, with medium liquidity risk and low dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Dae Hwa Pharm Co Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Han Gu LeeChairman of the Board, Chief Executive Officer